NICE backs breast cancer drug23rd November 2006
NICE has approved a new class of drugs in the treatment of older women with breast cancer.
The aromatase inhibitors (AIs) will now be available to treat women with hormone-sensitive tumours.
The approval brings the UK into line with most other European countries where the drugs have become standard treatment.
Professor Jeffrey Tobias of University College London said evidence shows the inhibitors work better than tamoxifen in reducing the chances of a recurrence of the disease.
The AIs work by suppressing production of oestrogen, which has been linked to breast cancer in post-menopausal women.
The decision is expected to affect around 23,000 women with newly diagnosed breast cancer and other patients already taking tamoxifen.
More than 40,000 women in the country are diagnosed with breast cancer each year.
Share this page
There are no comments for this article, be the first to comment!
Post your comment
Only registered users can comment. Fill in your e-mail address for quick registration.
Title: NICE backs breast cancer drug
Author: Martine Hamilton
Article Id: 1251
Date Added: 23rd Nov 2006